Clinical Trial Results:
            Multicenter, randomized Phase 2 Trial to determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) versus BAT in Steroid-refractory acute Graft-versus-Host Disease (aGvHD)
    
|     Summary | |
|     EudraCT number | 2014-004267-20 | 
|     Trial protocol | DE | 
|     Global completion date | |
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | |
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | |
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | |
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    20 Jan 2023
                             | 
|     First version publication date | 
                                    20 Jan 2023
                             | 
|     Other versions | |
|     Summary report(s) | RIG_result_summary | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
